Document is current
Any future updates will be listed below
-
Authors
Zeng, Jiali
Wu, Lanhua
Zeng, Qianru
Peng, Caijiao
Huang, Yubin
Ling, Li
-
Funding
Funding for this research was provided by:
The National Natural Science Foundation of China (82304959)
Natural Science Foundation of Chongqing (cstc2019jcyj-msxmX0850)
- License Information
-
More Information
Article History
Received: 22 June 2025
Accepted: 28 October 2025
First Online: 25 November 2025
Declarations
:
: The research was in compliance with the Helsinki Declaration and approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University. Written informed consent was obtained from all donors before collecting amnion. Animal experimental protocols were approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University in March 25, 2020. The approved project was entitled “Effects of Ginsenoside Rg1 combined with human amnion-derived mesenchymal stem cells (hAD-MSCs) on the chemotherapy-induced premature ovarian insufficiency (POI) (permit number 2020-20) ”.
: Not applicable.
: The authors declare no competing interests.
